^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lumakras (sotorasib) (KRAS G12C inhibitor) + avutometinib (VS-6766) (MEK inhibitor, BRAF inhibitor, cRAF inhibitor) + defactinib (VS-6063) (FAK inhibitor, Pyk2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1263 - Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS-G12C inhibitors through a vertical pathway inhibition strategy
Published date:
03/10/2021
Excerpt:
Similarly, in the H358 KRAS G12C mt NSCLC model, triple combination of VS-6766, sotorasib and a FAK inhibitor induced >35% tumor regression in 10/10 mice following 21 days of treatment.
